Company Filing History:
Years Active: 2013-2017
Title: Grégoire Alexandre Pavé: Innovator in Therapeutic Compounds
Introduction
Grégoire Alexandre Pavé is a notable inventor based in London, GB. He has made significant contributions to the field of therapeutic compounds, particularly in the development of innovative triazolo compounds. With a total of four patents to his name, Pavé's work focuses on compounds that have the potential to inhibit AXL receptor tyrosine kinase function, which is crucial in the treatment of various diseases, including cancer.
Latest Patents
Pavé's latest patents include [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds. These compounds are designed to inhibit AXL receptor tyrosine kinase function, which plays a significant role in the progression of proliferative conditions such as cancer. The inventions also encompass pharmaceutical compositions that utilize these compounds for therapeutic applications, both in vitro and in vivo.
Career Highlights
Grégoire Alexandre Pavé is currently associated with Cancer Research Technology Limited, where he continues to advance his research in therapeutic compounds. His work is pivotal in the ongoing fight against diseases mediated by AXL receptor tyrosine kinase, contributing to the development of effective treatments.
Collaborations
Pavé collaborates with esteemed colleagues, including James Donald Firth and Lorna Stewart. Their combined expertise enhances the research and development of innovative therapeutic solutions.
Conclusion
Grégoire Alexandre Pavé stands out as a significant figure in the field of therapeutic innovations. His contributions through patents and collaborations are paving the way for advancements in cancer treatment and other proliferative conditions.